Results 71 to 80 of about 59,458 (179)

Preparation and evaluation of W/O/W multiple emulsion containing naltrexone hydrochloride: a pilot study

, 2009
W/O/W multiple emulsions containing naltrexone (NTX) hydrochloride were prepared by a two-step emulsification method at 20 ºC. Characterization of the developed system was evaluated and the release kinetics of the drug was determined. The tissue response
Oliveira, Bérgson F., Ferreira, Ana E.R., Silva Cunha Júnior, Armando da, Fialho, Sílvia L.   +3 more
core  

Nefopam Hydrochloride: A Fatal Overdose [PDF]

, 2015
Nefopam is a non-opiate analgesic commonly used for the treatment of moderate to severe pain. A case of a 37-year-old male who was found dead in the morning is presented. An autopsy was performed and femoral venous blood, heart blood, urine, and vitreous
L. Nitin Seetohul, Drummond, Gail, Drummond, G., Nitin Seetohul, L., Gail Drummond, De Paoli, Giorgia; id_orcid, Seetohul, L. N., Seetohul, L. Nitin, Giorgia De Paoli, De Paoli, Giorgia, Maskell, Peter D., Peter D. Maskell, De Paoli, G.   +12 more
core   +1 more source

The cost effectiveness of naltrexone added to cognitive-behavioral therapy in the treatment of alcohol dependence

, 2009
The purpose of this study was to evaluate the comparative cost of treating alcohol dependence with either cognitive behavioral therapy (CBT) alone or CBT combined with naltrexone (CBT+naltrexone). Two hundred ninety-eight outpatients dependent on alcohol
Connor, Jason P., Feeney, Gerald F. X., Gerald F. X. Feeney, Walters, David, Young, Ross McD, Connors, Jason, Ross McD Young, David Walters, Jason P. Connor, Feeney, Gerald, Young, Ross McD.   +10 more
core   +1 more source

Investigation into the restoration of TRPM3 ion channel activity in post-COVID-19 condition: a potential pharmacotherapeutic target

Frontiers in Immunology
IntroductionRecently, we reported that post COVID-19 condition patients also have Transient Receptor Potential Melastatin 3 (TRPM3) ion channel dysfunction, a potential biomarker reported in natural killer (NK) cells from Myalgic Encephalomyelitis ...
Etianne Martini Sasso, Etianne Martini Sasso, Etianne Martini Sasso, Katsuhiko Muraki, Katsuhiko Muraki, Natalie Eaton-Fitch, Natalie Eaton-Fitch, Peter Smith, Peter Smith, Andrew Jeremijenko, Andrew Jeremijenko, Paul Griffin, Sonya Marshall-Gradisnik, Sonya Marshall-Gradisnik   +13 more
doaj   +1 more source

Naltrexone implant and blood naltrexone levels over pregnancy

, 2003
Approximately 80–90% of all women using intravenous heroin are of reproductive age. Although heroin use can cause menstrual irregularities such as amenorrhoea, oligomenorrhea and suppression of ovulation, pregnancy is not uncommon.
Hansson, Robert C, Hulse, Gary K, Arnold-Reed, Diane, O\u27Neil, George   +3 more
core   +1 more source

Improving clinical outcomes in treating heroin dependence: Randomized, controlled trial of oral or implant naltrexone [PDF]

, 2009
Context: Oral naltrexone hydrochloride effectively antagonizes heroin, but its utility is limited by patient noncompliance. Sustained-release preparations may overcome this limitation.
Hulse, Gary K, Tait, Robert J, Morris, N., Hulse, G., Arnold-Reed, D., Tait, Robert, Morris, Noella, Arnold-Reed, Diane, Hulse, Gary   +8 more
core   +1 more source

Intravenous abuse potential study of oxycodone alone or in combination with naltrexone in nondependent recreational opioid users

, 2016
Background: ALO-02, comprising pellets of extended-release oxycodone surrounding sequestered naltrexone, is intended to deter abuse. Objective: Determine the abuse potential of intravenous oxycodone combined with naltrexone, which represents simulated ...
Kenneth W. Sommerville (2796754), Bimal K. Malhotra (2796763), Miroslav Backonja (2796760), Almasa Bass (2796751), Kyle Matschke (2796748), Gernot Wolfram (2796769), Lynn R. Webster (2796766), Beatrice Setnik (2796757)   +7 more
core   +1 more source

A multicenter, primary care-based, open-label study to identify behaviors related to prescription opioid misuse, abuse, and diversion in opioid-experienced patients with chronic moderate-to-severe pain

Journal of Pain Research, 2015
Beatrice Setnik,1 Carl L Roland,1 Kenneth W Sommerville,1,2 Glenn C Pixton,1 Robert Berke,3,4 Anne Calkins,5 Veeraindar Goli1,2 1Pfizer Inc, 2Duke University Medical Center, Durham, NC, 3Family Health Medical Services PLLC, Mayville, NY, 4Department of ...
Setnik B, Rol, CL, Sommerville KW, Pixton GC, Berke R, Calkins A, Goli V   +7 more
doaj  

A multicenter, primary-care-based, open-label study to assess the success of converting opioid-experienced patients with chronic moderate-to-severe pain to morphine sulfate and naltrexone hydrochloride extended-release capsules using a standardized conversion guide

Journal of Pain Research, 2015
Beatrice Setnik,1 Carl L Roland,1 Kenneth W Sommerville,1,2 Glenn C Pixton,1 Robert Berke,3,4 Anne Calkins,5 Veeraindar Goli1,2 1Pfizer Inc, 2Duke University Medical Center, Durham, NC, USA; 3Family Health Medical Services PLLC, Mayville, 4Department of ...
Setnik B, Rol, CL, Sommerville KW, Pixton GC, Berke R, Calkins A, Goli V   +7 more
doaj  

Experience with an extended-release opioid formulation designed to reduce abuse liability in a community-based pain management clinic

International Journal of General Medicine, 2011
Daniel Rubino Pain Center of Devon, Devon, PA, USA Context: With the growing public health concern over rising rates of opioid abuse, physicians have a responsibility to incorporate safeguards into their practice to minimize the potential for opioid ...
Rubino D
doaj